Cytotoxicity of NF-κB inhibitors Bay 11-7085 and caffeic acid phenethyl ester to Ramos and other human B-lymphoma cell lines

Experimental Hematology

Volumn 35, Issue 10, 2007, Pages 1495-1509

  Berger, Nir ^a   Ben Bassat, Hannah ^b   Klein, Benjamin Y ^b   Laskov, Reuven ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BAY 117085; CAFFEIC ACID PHENETHYL ESTER; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SYNAPTOTAGMIN I; UNCLASSIFIED DRUG; BAY 11 7085; BAY 11-7085; CAFFEIC ACID DERIVATIVE; CYTOTOXIN; DRUG DERIVATIVE; NITRILE; PHENETHYL ALCOHOL; SULFONE; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL KILLING; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN MOTIF; ACTIVE TRANSPORT; B CELL LYMPHOMA; CELL CYCLE; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; PATHOLOGY; PROTEIN BINDING; TIME; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; CAFFEIC ACIDS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; CYTOPLASM; CYTOTOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LYMPHOMA, B-CELL; MEMBRANE POTENTIAL, MITOCHONDRIAL; NECROSIS; NITRILES; PHENYLETHYL ALCOHOL; PROTEIN BINDING; SULFONES; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 34548727373     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.07.006     Document Type: Article

References (53)

1. Amit S., and Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol 13 (2003) 15-28
2. Rayet B., and Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18 (1999) 6938-6947
3. Wood K.M., Roff M., and Hay R.T. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene 16 (1998) 2131-2139
4. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dorken B., and Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 18 (1999) 943-953
5. Staudt L.M. The molecular and cellular origins of Hodgkin's disease. J Exp Med 191 (2000) 207-212
6. Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B-cell-like diffuse large B-cell lymphoma cells. J Exp Med 194 (2001) 1861-1874
7. Sonenshein G.E. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol 8 (1997) 113-114
8. Epinat J.C., and Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 18 (1999) 6896-6909
9. Celec P. Nuclear factor kappa B-molecular biomedicine: the next generation. Biomed Pharmacother 58 (2004) 365-371
10. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3 (2004) 17-26
11. Pande V., and Ramos M.J. NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. Curr Med Chem 12 (2005) 357-374
12. Voorhees P.M., and Orlowski R.Z. Emerging role of novel combinations for induction therapy in multiple myeloma. Clin Lymphoma Myeloma 7 (2006) 33-41
13. Pierce J.W., Schoenleber R., Jesmok G., et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272 (1997) 21096-21103
14. Natarajan K., Singh S., Burke Jr. T.R., Grunberger D., and Aggarwal B.B. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A 93 (1996) 9090-9095
15. Hu X., Janssen W.E., Moscinski L.C., et al. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res 61 (2001) 6290-6296
16. Laskov R., Berger N., Scharff M.D., and Horwitz M.S. Tumor necrosis factor-alpha and CD40L modulate cell surface morphology and induce aggregation in Ramos Burkitt's lymphoma cells. Leuk Lymphoma 47 (2006) 507-519
17. Scudiero D.A., Shoemaker R.H., Paull K.D., et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48 (1988) 4827-4833
18. Schreiber E., Matthias P., Muller M.M., and Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17 (1989) 6419
19. Staal A., van Wijnen A.J., Birkenhager J.C., et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specified by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 10 (1996) 1444-1456
20. Zou W., Amcheslavsky A., and Bar-Shavit Z. CpG oligodeoxynucleotides modulate the osteoclastogenic activity of osteoblasts via Toll-like receptor 9. J Biol Chem 278 (2003) 16732-16740
21. Robertson J.D., and Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 30 (2000) 609-627
22. Zhang J.H., and Xu M. DNA fragmentation in apoptosis. Cell Res 10 (2000) 205-211
23. Harkin S.T., Cohen G.M., and Gescher A. Modulation of apoptosis in rat thymocytes by analogs of staurosporine: lack of direct association with inhibition of protein kinase C. Mol Pharmacol 54 (1998) 663-670
24. Marchetti P., Castedo M., Susin S.A., et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184 (1996) 1155-1160
25. Zamzami N., Susin S.A., Marchetti P., et al. Mitochondrial control of nuclear apoptosis. J Exp Med 183 (1996) 1533-1544
26. Maeno E., Ishizaki Y., Kanaseki T., Hazama A., and Okada Y. Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci U S A 97 (2000) 9487-9492
27. Okada Y., Shimizu T., Maeno E., Tanabe S., Wang X., and Takahashi N. Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. J Membr Biol 209 (2006) 21-29
28. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev 18 (2004) 2195-2224
29. Laskov R., Berger N., and Horwitz M.S. Differential effects of tumor necrosis factor-alpha and CD40L on NF-kappaB inhibitory proteins IkappaBalpha, beta and epsilon and on the induction of the Jun amino-terminal kinase pathway in Ramos Burkitt lymphoma cells. Eur Cytokine Netw 16 (2005) 267-276
30. Leung C.H., Grill S.P., Lam W., Han Q.B., Sun H.D., and Cheng Y.C. Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol Pharmacol 68 (2005) 286-297
31. Nagaoka T., Banskota A.H., Tezuka Y., Saiki I., and Kadota S. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. Bioorg Med Chem 10 (2002) 3351-3359
32. Keller S.A., Schattner E.J., and Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96 (2000) 2537-2542
33. Zarnegar B., He J.Q., Oganesyan G., Hoffmann A., Baltimore D., and Cheng G. Unique CD40-mediated biological program in B-cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc Natl Acad Sci U S A 101 (2004) 8108-8113
34. Bohuslav J., Chen L.F., Kwon H., Mu Y., and Greene W.C. p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 279 (2004) 26115-26125
35. Lesokhin A.M., Delgado-Lopez F., and Horwitz M.S. Inhibition of chemokine expression by adenovirus early region three (E3) genes. J Virol 76 (2002) 8236-8243
36. Clerk A., and Sugden P.H. The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426 (1998) 93-96
37. Cahir-McFarland E.D., Carter K., Rosenwald A., et al. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78 (2004) 4108-4119
38. Relic B., Benoit V., Franchimont N., et al. 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 279 (2004) 22399-22403
39. Kapahi P., Takahashi T., Natoli G., et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 275 (2000) 36062-36066
40. Mathas S., Lietz A., Janz M., et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102 (2003) 1028-1034
41. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
42. Bain J., McLauchlan H., Elliott M., and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371 (2003) 199-204
43. Liou H.C., Sha W.C., Scott M.L., and Baltimore D. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 14 (1994) 5349-53459
44. Siebenlist U., Brown K., and Claudio E. Control of lymphocyte development by nuclear factor-kappaB. Nat Rev Immunol 5 (2005) 435-445
45. Goudeau B., Huetz F., Samson S., et al. IkappaBalpha/IkappaBepsilon deficiency reveals that a critical NF-kappaB dosage is required for lymphocyte survival. Proc Natl Acad Sci U S A 100 (2003) 15800-15805
46. Gerondakis S., and Strasser A. The role of Rel/NF-kappaB transcription factors in B lymphocyte survival. Semin Immunol 15 (2003) 159-166
47. Pham L.V., Tamayo A.T., Yoshimura L.C., Lo P., and Ford R.J. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B-cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171 (2003) 88-95
48. Dai Y., Pei X.Y., Rahmani M., Conrad D.H., Dent P., and Grant S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103 (2004) 2761-2770
49. Mori N., Yamada Y., Ikeda S., et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100 (2002) 1828-1834
50. Zhong H., May M.J., Jimi E., and Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 9 (2002) 625-636
51. Chen L.F., Mu Y., and Greene W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21 (2002) 6539-6548
52. Berger S.L. Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12 (2002) 142-148
53. Rundall B.K., Denlinger C.E., and Jones D.R. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 136 (2004) 416-425